9/28/26 +5% since 7/1

The Daybreak clinical trial establishes a new benchmark for wet AMD treatment by utilizing a "treat-to-dry" retreatment algorithm that closely mirrors real-world clinical practice. Tarcosamab achieved non-inferiority to aflibercept, with data suggesting that its biopolymer conjugate significantly extends intraocular half-life, allowing for longer dosing intervals across a broad patient population. While wet AMD is primarily VEGF-driven, the discussion highlights the potential for IL-6 inhibition in diabetic macular edema (DME), where inflammatory components are more prevalent. Experts emphasize that future management will shift toward an oncology-like approach, targeting specific patient subpopulations through advanced imaging and biomarker analysis. This strategy aims to address disease activity before significant visual acuity loss or architectural damage occurs, marking a transition toward more nuanced, personalized therapeutic interventions in retinal care.